Oyster Point Pharma v. Apotex: Varenicline Dry Eye Patents Secured by Consent Judgment
Oyster Point Pharma filed suit in the District of New Jersey against generic manufacturer Apotex over 10 patents covering varenicline-based treatments for dry eye disease. After 799 days of litigation, the parties resolved the dispute via a stipulated consent judgment — enjoining Apotex from commercialising its ANDA No. 217954 product until all 10 patents expire.
ANDA challenge to varenicline dry eye portfolio ends in injunction for Oyster Point
Oyster Point Pharma, Inc. filed this Hatch-Waxman infringement action on 19 July 2023 in the U.S. District Court for the District of New Jersey, asserting ten patents covering varenicline nasal spray compositions, pharmaceutical formulations, and methods of treating dry eye disease — including increasing tear production and improving ocular comfort. The suit was triggered by Apotex’s ANDA No. 217954, a generic drug application seeking to market a varenicline product in the United States before the expiry of Oyster Point’s patent estate.
The case closed on 25 September 2025 through a stipulated consent judgment and injunction — a negotiated resolution in which all claims, counterclaims, and affirmative defences were dismissed without prejudice. Critically, Apotex and anyone acting on its behalf was enjoined from making, using, offering to sell, selling, or importing ANDA No. 217954 products in the United States until the expiry of all ten asserted patents. Each party bears its own legal costs, and the court retains jurisdiction to enforce the agreement.
A resolution at 799 days — before any full merits adjudication — is consistent with negotiated settlements common in ANDA litigation where the brand holder secures market exclusivity via injunction rather than litigation risk. The public record does not disclose any royalty, licensing payment, or authorised-generic agreement, though such terms are frequently part of related private settlements referenced in consent judgments of this type. What drove the agreed injunction — strength of the patent claims, Apotex’s validity assessment, or commercial considerations — is not determinable from the public record.
Filing to Consent Judgment in 799 days
799 days — slightly above median ANDA litigation duration before trial
Consent judgment with injunction: what the stipulated resolution means for both parties
Consent judgment: a negotiated court order with binding injunctive force
A stipulated consent judgment is a court-entered order agreed to by both parties. Unlike a voluntary dismissal alone, this resolution carries permanent injunctive effect: Apotex is legally barred from commercialising its ANDA product until all ten patents expire. All claims were dismissed without prejudice, meaning neither party received a formal merits ruling, but the injunction is fully enforceable by the court, which retains jurisdiction.
Dismissed without prejudice + injunctionOyster Point secures exclusivity across its entire 10-patent dry eye portfolio
The consent judgment delivers the commercially critical result for Oyster Point: Apotex cannot launch a generic varenicline product in the U.S. market for the life of any of the ten asserted patents. By obtaining an injunction rather than proceeding to trial, Oyster Point avoids the risk of an invalidity finding that could have destabilised the broader patent estate protecting Tyrvaya. The patents-in-suit span compositions, formulations, and multiple method claims — providing layered enforcement coverage.
Market exclusivity preservedApotex enjoined from ANDA No. 217954 commercialisation until patent expiry
Apotex agreed to an injunction covering all ten patents, effectively conceding market entry on the terms asserted by Oyster Point. The dismissal without prejudice technically leaves open the possibility of future patent challenges through alternate routes such as IPR petitions at the USPTO, though the consent judgment’s private related agreements — not publicly disclosed — may include additional constraints. Apotex faces no damages liability under this resolution, but foregoes near-term generic market entry.
Market entry blocked; no damagesTyrvaya’s IP moat reinforced — implications for the dry eye generics landscape
The consent judgment reinforces the strength of Oyster Point’s (now AstraZeneca subsidiary) varenicline nasal spray IP position. Other potential ANDA filers targeting the same product must contend with a 10-patent portfolio that has now survived a generic challenge without any claim being adjudicated invalid. This outcome typically signals to follow-on challengers that the patent holder is prepared to litigate aggressively and negotiate from strength, raising the risk calculus for future Paragraph IV certifications.
Strong deterrent for follow-on ANDA filersFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Oyster Point Pharma, Inc. | Company | Pharmaceutical innovator — holder of 10 U.S. patents covering varenicline dry eye therapy (Tyrvaya)Search in Eureka ↗ |
| Defendant | Apotex, Inc. | Company | Canadian generic pharmaceutical manufacturer seeking U.S. market entry via ANDA No. 217954Search in Eureka ↗ |
| Plaintiff counsel | Gregory D. Miller | Attorney | Counsel for Oyster Point Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Rivkin Radler LLP | Law Firm | Representing Oyster Point Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Kristine L. Butler | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephanie-Rose Orlando | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Tyler Doh | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | VISHAL CHANDRA GUPTA | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack, LLP | Law Firm | Representing Apotex, Inc.Search in Eureka ↗ |
| Defendant law firm | Steptoe, LLP | Law Firm | Representing Apotex, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consent judgment is notable for its scope: it names all ten asserted patents individually and enjoins not only Apotex but ‘anyone acting on behalf of Apotex,’ suggesting the parties sought to prevent circumvention through subsidiaries or partners. The without-prejudice dismissal of claims and counterclaims means no court has ruled on validity or infringement — the injunction derives entirely from Apotex’s contractual agreement, not adjudicated patent strength. The court’s retained jurisdiction to enforce the judgment and ‘related agreements’ confirms this is a comprehensive settlement structure, not merely a procedural close.
US9504644B2 and portfolio — varenicline nasal spray compositions and dry eye methods
The asserted portfolio covers varenicline — a nicotinic acetylcholine receptor partial agonist originally known as a smoking-cessation agent — repurposed for intranasal delivery to stimulate the trigeminal-parasympathetic pathway and increase natural tear production. The ten U.S. patents span compositions (US9504644, US9504645, US9532944, US9597284), broader method-of-use and formulation claims (US10456396, US11224598), and a cluster of 2022–2023 continuation patents (US11903941, US11903942, US11903943, US11911380) filed as the product approached commercialisation. The continuation filings extend protection well beyond the original application dates.
Commercially, these patents protect Tyrvaya (varenicline solution) nasal spray — the first FDA-approved nasal spray for dry eye disease, approved in October 2021. The product addresses a large and growing patient population where topical eye drops face compliance challenges. The continuation-heavy structure of the portfolio is strategically significant: it creates a rolling expiry schedule that is difficult for generics to design around, and the breadth of method claims — covering tear production, lacrimal protein secretion, and ocular discomfort separately — means any varenicline nasal spray product targeting dry eye is likely to face multiple independent infringement theories.
Should you run an FTO against the Oyster Point varenicline dry eye patent portfolio?
Any company developing or formulating a varenicline-containing product for ophthalmic or nasal delivery — or exploring nicotinic receptor agonists for dry eye therapy — should treat this portfolio as an active enforcement risk. The consent judgment confirms Oyster Point (and by extension AstraZeneca) is willing to seek injunctions against ANDA filers, and the ten-patent estate covers compositions, multiple method-of-use angles, and pharmaceutical formulations. R&D teams working on dry eye, nasal drug delivery, or tear-stimulating therapeutics should conduct an FTO before IND filing or formulation lock.
PatSnap Eureka’s FTO Search Agent can map your compound, delivery mechanism, or method of use against the full claim scope of all ten patents in this portfolio, flag continuation applications still pending at the USPTO, and identify prior art that may support design-around or IPR strategies. Given the breadth of continuation filings, a live patent family monitor is also advisable — new claims may issue from pending applications not yet publicly visible.
Run a freedom-to-operate analysis on US9504644B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA dry eye pharmaceutical patent cases in New Jersey District Court
Hatch-Waxman infringement actions involving ophthalmic or dry eye pharmaceutical patents filed in the District of New Jersey — comparable ANDA enforcement patterns and resolution types.
What this case signals for the ophthalmic pharmaceutical IP landscape
Oyster Point’s consent judgment win illustrates how layered patent portfolios can neutralise ANDA threats before trial in specialty pharma.
Portfolio depth — not single-patent strength — is the decisive ANDA defence
Oyster Point asserted ten patents spanning compositions, methods, and formulations. This layered approach forces generic challengers to invalidate an entire patent family — a far higher burden than attacking a single claim. Pharma IP teams protecting NCE or NME products should build portfolio depth across all claim types from the earliest prosecution stage.
Consent judgments with injunctions are effective tools in Hatch-Waxman strategy
Securing a permanent injunction via consent judgment avoids the risk of an adverse invalidity ruling at trial while delivering the core commercial objective: blocking generic entry. Brand pharmaceutical companies with strong portfolios should model this outcome as an alternative to full trial, particularly where maintaining patent validity across all claims is strategically important.
Oyster v Apotex — key questions answered
The case was resolved on 25 September 2025 via a stipulated consent judgment and injunction. All claims were dismissed without prejudice, and Apotex was permanently enjoined from making, using, selling, or importing its ANDA No. 217954 varenicline product in the United States until the expiry of all ten asserted patents. Each party bears its own legal costs.
Oyster Point asserted ten U.S. patents: US9504644B2, US9504645B2, US9532944B2, US9597284B2, US10456396B2, US11224598B2, US11903941B2, US11903942B2, US11903943B2, and US11911380B2. These cover varenicline compositions, pharmaceutical formulations, and multiple methods of treating dry eye disease including increasing tear production, lacrimal protein secretion, and improving ocular discomfort.
In this case, ‘dismissed without prejudice’ means no court adjudicated the validity or infringement of the patents on the merits. However, the dismissal is accompanied by a binding consent judgment and permanent injunction — meaning the practical effect is that Apotex cannot commercialise its ANDA product. The without-prejudice status technically preserves the ability to re-litigate or pursue USPTO post-grant challenges, subject to any private agreement terms.
The public consent judgment dismissed all claims without prejudice and does not explicitly bar future patent office proceedings. Apotex could theoretically file IPR petitions at the USPTO, subject to the one-year statutory bar and any constraints in the parties’ undisclosed related agreements. However, the injunction against ANDA No. 217954 remains in force regardless of any future USPTO proceedings, unless a court orders otherwise.
ANDA No. 217954 is Apotex’s Abbreviated New Drug Application filed with the FDA seeking approval to market a generic version of a varenicline-based nasal spray product for dry eye disease — the product category covered by Oyster Point’s Tyrvaya (varenicline solution) nasal spray. The ANDA’s Paragraph IV certification triggered Oyster Point’s infringement lawsuit under the Hatch-Waxman Act.
PatSnap Eureka searches patents and litigation data to answer instantly.